Evidence map›Paper›PMID 33615283›Full record

ArticleF&S reviews2021

Exogenous testosterone replacement therapy versus raising endogenous testosterone levels: current and future prospects.

Kajal Khodamoradi, Zahra Khosravizadeh, Madhu Parmar, Manish Kuchakulla, Ranjith Ramasamy, Himanshu Arora

Open access · greenAbstract read
In one paragraph

Article in F&S reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Curcumin enhances the oral bioavailability of testosterone by inhibiting its intestinal metabolism.Drug metabolism and disposition: the biological fate of chemicals · 2025
    Trial
  2. Article
  3. Review
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Testosterone propionate andInternational journal of reproductive biomedicine · 2023
    Article
  11. Review
  12. Review
  13. The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.International journal of molecular sciences · 2022
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Kajal KhodamoradiDepartment of Urology, Miller School of Medicine, University of Miami, 1600 NW 10th Ave #1140, Miami, FL 33136, USA.
Zahra KhosravizadehDepartment of Urology, Miller School of Medicine, University of Miami, 1600 NW 10th Ave #1140, Miami, FL 33136, USA.
Madhu ParmarDepartment of Urology, Miller School of Medicine, University of Miami, 1600 NW 10th Ave #1140, Miami, FL 33136, USA.
Manish KuchakullaDepartment of Urology, Miller School of Medicine, University of Miami, 1600 NW 10th Ave #1140, Miami, FL 33136, USA.
Ranjith RamasamyDepartment of Urology, Miller School of Medicine, University of Miami, 1600 NW 10th Ave #1140, Miami, FL 33136, USA.
Himanshu AroraDepartment of Urology, Miller School of Medicine, University of Miami, 1600 NW 10th Ave #1140, Miami, FL 33136, USA.
University of Miami · US

Funding

Miami Clinical and Translational Science InstituteUL1TR000460 · NCATS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SACCO, RALPH L. · 2012 to 2016
$16.9M
NCATS NIH HHS UL1 TR000460
6 · The paper itself

Abstract

Testosterone replacement therapy is an important treatment option for men with low testosterone and symptomatic hypogonadism. Various formulations of exogenous testosterone replacement therapy exist, including oral, buccal, intramuscular, transdermal, subdermal, and nasal preparations. However, exogenous testosterone replacement therapy is a double-edged sword, posing risks to fertility due to negative feedback mechanisms on the hypothalamic-pituitary-gonadal (HPG) axis, which is the main regulator of testosterone production and spermatogenesis in males. Alternative pharmacologic therapies are being used to increase endogenous testosterone levels while attempting to preserve fertility and function of the HPG axis. These include selective estrogen receptor modulators, gonadotropins, and aromatase inhibitors. This review focuses on overviewing and comparing the currently available methods of exogenous testosterone replacement therapy, alternative treatments to increasing endogenous testosterone, and novel treatments that are currently under investigation to normalize testosterone levels while preserving the function of the HPG axis. In conclusion, reports suggest that, though Testosterone replacement therapy is an important way to restore testosterone levels and reduce symptoms associated with low testosterone, it is often difficult to decide which treatment to select for patients with testosterone deficiency. Several factors need to be considered to decide on optimal therapy option for the patient which include but are not limited to safety, efficacy, cost-effectiveness, dosing flexibility, and side effects. Alternative approaches which aim to improve endogenous testosterone production and preserve fertility are promising but still are at their initial stages of development. Ultimately, patient-centered decision making is paramount to appropriate treatment selection.

Indexed as

hypothalamic-pituitary-gonadal axislow testosteronemale infertilitytestosterone replacement therapy

Identifiers

PMID33615283
PMCPMC7894643
OpenAlexW3103791475

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.